Jiapeng Xu

588 citations
24 papers · 438 indexed · h-index 11
Topics
Cancer-related molecular mechanisms research (6 papers)RNA modifications and cancer (5 papers)MicroRNA in disease regulation (4 papers)

In The Last Decade

Jiapeng Xu

23 papers receiving 430 citations

Peers

Jiapeng Xu
Comparison fields: 5 of 67
  • Molecular Biology 279
  • Cancer Research 135
  • Molecular Medicine 76
  • Oncology 64
  • Epidemiology 60
Replace Zunqi Hu with:
Zunqi Hu China
Fuqiang Feng China
Xiali Tang China
Weiwen Chen China
Zhan‐Qi Cao China
Pihong Li China
Yingchun He China
Yongqiang Hou China
Xinguo Zhu China
Siriporn Keeratichamroen Thailand
Jiapeng Xu relative to Zunqi Hu China Zunqi Hu's profile →
Citations per field
00.5×
Zunqi Hu · 1×
Citations per year

Countries citing papers authored by Jiapeng Xu

Since Specialization
Citations

This map shows the geographic impact of Jiapeng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiapeng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiapeng Xu more than expected).

Fields of papers citing papers by Jiapeng Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiapeng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiapeng Xu. The network helps show where Jiapeng Xu may publish in the future.

Co-authorship network of co-authors of Jiapeng Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Jiapeng Xu. A scholar is included among the top collaborators of Jiapeng Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiapeng Xu. Jiapeng Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 3
3 8
4 6
5 28
6 2
7 8
8 9
9 16
10
miR-519 inhibits epithelial-mesenchymal transition and biologic behavior of gastric cancer cells by down-regulating FOXQ1.
9
11 9
12 19
13 22
14 32
15 46
16 152
17 15
18 3
19 18
20 14

About Jiapeng Xu

Jiapeng Xu is a scholar working on Cancer Research, Applied Microbiology and Biotechnology and Immunology and Allergy, having authored 24 papers that have together received 438 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (6 papers), RNA modifications and cancer (5 papers) and MicroRNA in disease regulation (4 papers). The work is most often cited by research in Molecular Medicine (76 citations), Cancer Research (135 citations) and Molecular Biology (279 citations). Jiapeng Xu has collaborated with scholars based in China, Canada and United Kingdom. Frequent co-authors include Zunqi Hu, Dejun Yang, Hongbing Fu, Ronglin Yan, Ziran Wei, Qingping Cai, Zhenxin Zhu, Changming Wang, Weimin Wang and Yu Zhang. Their work appears in journals such as Biochemical and Biophysical Research Communications, Journal of Cellular Physiology and Carcinogenesis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026